Evidence map›Paper›PMID 22050417›Full record

ArticleInternational journal of experimental pathology2011

Morphofunctional changes underlying intestinal dysmotility in diabetic RIP-I/hIFNβ transgenic mice.

Anna Domènech, Gianandrea Pasquinelli, Roberto De Giorgio, Alessandra Gori, Fàtima Bosch, Martí Pumarola, Marcel Jiménez

Open access · greenAbstract read
In one paragraph

Article in International journal of experimental pathology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 44 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. CNS-Sparing Histamine HBiomolecules · 2022
    Article
  6. Article
  7. Enhanced Store-Operated CaFrontiers in physiology · 2021
    Article
  8. Article
  9. Diabetes and the Small Intestine.Current treatment options in gastroenterology · 2017
    Review
  10. Diabetes Mellitus and the Colon.Current treatment options in gastroenterology · 2017
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Hepatic insulin gene therapy prevents diabetic enteropathy in STZ-treated CD-1 mice.Molecular therapy. Methods & clinical development · 2015
    Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Anna DomènechDepartment of Animal Medicine and Surgery, Universitat Autònoma de Barcelona, Bellaterra, Spain. anna.domenech@uab.es
Gianandrea Pasquinelli
Roberto De Giorgio
Alessandra Gori
Fàtima Bosch
Martí Pumarola
Marcel Jiménez
Universitat Autònoma de Barcelona · ESUniversity of Bologna · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The pathogenetic mechanisms underlying gastrointestinal dysmotility in diabetic patients remain poorly understood, although enteric neuropathy, damage to interstitial cells of Cajal (ICC) and smooth muscle cell injury are believed to play a role. The aim of this study was to investigate the morphological and functional changes underlying intestinal dysmotility in RIP-I/hIFNβ transgenic mice treated with multiple very low doses of streptozotocin (20 mg/kg, i.p., 5 days). Compared with vehicle-treated mice, streptozotocin-treated animals developed type 1 diabetes mellitus, with sustained hyperglycaemia for 3.5 months, polyphagia, polydipsia and increased faecal output without changes in faecal water content (metabolic cages). Diabetic mice had a longer intestine, longer ileal villi and wider colonic crypts (conventional microscopy) and displayed faster gastric emptying and intestinal transit. Contractility studies showed selective impaired neurotransmission in the ileum and mid-colon of diabetic mice. Compared with controls, the ileal and colonic myenteric plexus of diabetic mice revealed ultrastructural features of neuronal degeneration and HuD immunohistochemistry on whole-mount preparations showed 15% reduction in neuronal numbers. However, no immunohistochemical changes in apoptosis-related markers were noted. Lower absolute numbers of neuronal nitric oxide synthase- and choline acetyltransferase-immunopositive neurons and enhanced vasoactive intestinal polypeptide and substance P immunopositivity were observed. Ultrastructural and immunohistochemical analyses did not reveal changes in the enteric glial or ICC networks. In conclusion, this model of diabetic enteropathy shows enhanced intestinal transit associated with intestinal remodelling, including neuroplastic changes, and overt myenteric neuropathy. Such abnormalities are likely to reflect neuroadaptive and neuropathological changes occurring in this diabetic model.

Indexed as

AnimalsCholine O-AcetyltransferaseColonDiabetes Mellitus, ExperimentalDiabetes Mellitus, Type 1Diabetic NeuropathiesDisease Models, AnimalGastric EmptyingGastrointestinal MotilityIleumInterferon-betaMaleMiceMice, TransgenicMyenteric PlexusNitric Oxide Synthase Type ICholine O-AcetyltransferaseInterferon-betaNitric Oxide Synthase Type IReceptor-Interacting Protein Serine-Threonine KinasesStreptozocinSubstance PVasoactive Intestinal Peptide

Identifiers

PMID22050417
PMCPMC3248076
OpenAlexW2099200038

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.